11/14
11:10 am
mcrb
Rating for MCRB
Low
Report
Rating for MCRB
11/13
07:42 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
11/13
06:55 pm
mcrb
Rating for MCRB
Low
Report
Rating for MCRB
10/24
07:16 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
10/24
07:06 am
mcrb
Rating for MCRB
Medium
Report
Rating for MCRB